CASSEY SIMONS: Open Payments
NPI 1356038368 · EL DORADO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$797 in 22 payments from 7 companies in 2025. Trend: 2023 $142 · 2024 $177 · 2025 $797
Food & beverage: $797
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 7 | $407 |
| Neurocrine BioSciences, Inc. | 8 | $164 |
| SANOFI-AVENTIS U.S. LLC | 1 | $96 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Alkermes, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
Products named: COBENFY, INGREZZA, TZIELD, ABILIFY ASIMTUFII, VIVITROL, REXULTI, VRAYLAR, UZEDY.
Industry payments across AR — which companies pay providers there.
